ExCellThera is developing novel curative therapies for patients with hematologic malignancies and other diseases. To learn more about our ongoing clinical trials, please view our program pipeline.
ExCellThera is pioneering best-in-class clinical trials in various indications in an effort to get cures to patients in an effective and efficient manner.
ECT-001 (UM171) Expanded Cord Blood Transplant in Patients in Need of an Allogeneic Stem Cell Transplant – https://clinicaltrials.gov/ct2/show/NCT02668315
ECT-001 (UM171) Expanded Cord Blood Transplant In Patients With High-Risk Acute Leukemia/Myelodysplasia – https://clinicaltrials.gov/ct2/show/NCT03913026
ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma – https://clinicaltrials.gov/ct2/show/NCT03441958
ECT-001 (UM171) Expanded Cord Blood in US Patients With High Risk Leukemia/Myelodysplasia – https://clinicaltrials.gov/ct2/show/NCT04103879
ECT-001 (UM171) Expanded Cord Blood Transplant in Patients With Sickle-Cell Disease – https://clinicaltrials.gov/ct2/show/NCT04594031
ECT-001 (UM171) Expanded Cord Blood Transplant in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies – https://clinicaltrials.gov/ct2/show/NCT04990323